| Identification | Back Directory | [Name]
scopolin | [CAS]
531-44-2 | [Synonyms]
5Mg
CPD-678
Murrayin
Scopoloside
Scopoletin glucoside
Scopoletin 7-O-Glucoside
scopoletin-β-D-galactoside
6-Methoxycoumarin 7-O-beta-D-glucoside
6-Methoxy-7-(beta-D-glucopyranosyloxy)coumarin
7-(beta-D-Glucopyranosyloxy)-6-methoxycoumarin
2H-1-Benzopyran-2-one, 7-(β-D-glucopyranosyloxy)-6-methoxy-
7-(beta-D-Glucopyranosyloxy)-6-methoxy-2H-1-benzopyran-2-one
6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one | [Molecular Formula]
C16H18O9 | [MDL Number]
MFCD02259444 | [MOL File]
531-44-2.mol | [Molecular Weight]
354.309 |
| Chemical Properties | Back Directory | [Melting point ]
217℃ | [Boiling point ]
650.2±55.0 °C(Predicted) | [density ]
1.552 | [storage temp. ]
2-8°C | [solubility ]
Soluble in DMSO | [form ]
powder | [pka]
12.71±0.70(Predicted) | [color ]
White |
| Hazard Information | Back Directory | [Uses]
Scopoletin 7-O-glucoside is a derivative of Scopoletin (S200500), a common constituent found in a variety of plants that has potential to regulate hyperthyroidism in rats. Scopoletin 7-O-glucoside is a compound that is obtained from the methanolic extract of the fresh underground parts of the flower Scopolia japonica. | [Definition]
ChEBI: A member of the class of coumarins that is scopoletin attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. | [in vivo]
Scopolin (0.02% (w/w) in HFD diet, 8 weeks) decreases the body weight gain, and alleviates hepatic steatosis in HFD-fed mice[2].
Scopolin (2 μmol, icv) increases the extracellular acetylcholine concentration in rat brain to about 300% compared to basal release[3].
Scopolin (50, 100 mg/kg, i.p.) inhibits adjuvant-induced arthritis by inhibiting inflammation and angiogenesis in rats[4].
| Animal Model: | HFD-fed C57BL/6?N mice[2] | | Dosage: | 0.02% (w/w) in HFD diet (equivalent to 20?mg/kg body weight) | | Administration: | Supplemented in diet, 8 weeks | | Result: | Reversed the HFD-induced hepatic TG, cholesterol, and fatty acid accumulation by 35%, 49%, and 35%, respectively.
Reversed the HFD-induced decrease in plasma adiponectin levels by 76%, and reduced the increased plasma MCP-1, TNFα, and IL-6 levels.
Restored HFD-induced downregulation of SIRT1 activity. |
| Animal Model: | Adjuvant-induced arthritis (AIA) rats[4] | | Dosage: | 50, 100 mg/kg | | Administration: | i.p. | | Result: | Inhibited inoculated and non-inoculated paw swelling and articular index scores.
Reduced new blood vessels, and reduced IL-6, VEGF and FGF-2 expressions in rat synovial tissues. |
| [target]
VEGFR | IL Receptor | AChR | Antifection | [IC 50]
SIRT1 | [storage]
Store at -20°C |
|
|